The worldwide prevalence of chronic kidney disease is 10–15 % of the adult population, is rising and increases susceptibility to venous thromboembolism (VTE). In this narrative review we discuss the underlying evidence behind the association of VTE/CKD and examine the role of worsening CKD stage, proteinuria, and the risk of recurrent VTE. As CKD may alter therapeutic options we discuss the role of emerging therapies, the non-vitamin K oral anticoagulants (NOAC), in the treatment of VTE.
- Chronic kidney disease
- Non-vitamin K antagonist oral anticoagulants
- Venous thromboembolism
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine